Artemis Medicare Services Limited shareholders have approved the appointment of Dr. Girdhar Jessaram Gyani as an Independent Director, strengthening the Board’s governance framework with deep healthcare industry expertise. The resolution was passed at the company’s 22nd Annual General Meeting (AGM) held on July 31, 2026, with voting results declared later that evening at 7:39 P.M. Dr. Gyani’s tenure is set for a period of three consecutive years, commencing on August 1, 2026, and concluding on July 31, 2029.

The appointment was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Artemis Medicare Services Limited confirmed that Dr. Gyani is not debarred from holding the office of a Director by the Securities and Exchange Board of India (SEBI) or any other authority. The Company Secretary and Compliance Officer, Poonam Makkar, issued the disclosure to both the National Stock Exchange of India Limited and BSE Limited following the AGM.

Director Profile and Expertise

Dr. Girdhar Jessaram Gyani brings extensive experience in healthcare quality standards and accreditation to the Board. He currently serves as the Director General of the Association of Healthcare Providers (India) (AHPI), a not-for-profit society representing a vast majority of private hospitals in India. Prior to this role, he served as the Secretary General of the Quality Council of India from 2003 to 2012.

A key highlight of his career is his role in establishing the National Accreditation Board for Hospitals (NABH), where he served as CEO until his superannuation in May 2012. This contribution helped create the first national accreditation structure for healthcare in the country. His expertise has been recognized by industry publications, including SME World Magazine, which described him as the 'Quality Man of India' in June 2012, and Healthcare Executive magazine, which recognized him as the 'CHANAKYA of Healthcare Quality' in January 2015.

Dr. Gyani holds a graduation degree from Agra University and completed his doctorate from Indraprastha University. The filing confirms there are no relationships between Dr. Gyani and any other Director of the Company.

Key Appointment Details

Governance Implications

The addition of an Independent Director with specialized knowledge in hospital accreditation and quality management supports Artemis Medicare Services Limited’s commitment to high clinical and operational standards. As the company continues to expand its multi-specialty hospital network, including brands such as Artemis Cardiac Care and Daffodil Luxury Mother & Child Centre, the Board’s oversight benefits from Dr. Gyani’s background in national healthcare policy and quality assurance frameworks.

Artemis Medicare Services has announced that Sanjib Sen has ceased to be a Director of the company effective August 2, 2026. The departure follows the completion of his tenure as an Independent Director, marking a routine transition in the Board’s composition rather than a sudden exit. This change affects the independent director segment of the Board, which plays a critical role in governance and oversight for listed entities in India.

The disclosure was made on August 3, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Poonam Makkar, Company Secretary and Compliance Officer of Artemis Medicare Services, signed the notification sent to the National Stock Exchange of India Limited and BSE Limited. The filing confirms that Sen’s departure is due solely to the expiration of his term, with no adverse reasons or conflicts cited.

Details of Cessation

The regulatory filing provides specific details regarding the change in directorship. Sanjib Sen, identified by DIN 07088442, held the position of Independent Director. His tenure concluded on August 2, 2026. The company has not provided a brief profile or disclosure of relationships in this specific filing, as these fields are marked "Not Applicable" for cessations under the relevant schedule.

Governance Implications

The loss of an Independent Director reduces the number of independent members on the Board until a successor is appointed. Listed companies in India are required to maintain a minimum proportion of Independent Directors to ensure objective oversight of management and protect minority shareholder interests. Artemis Medicare Services must now initiate the process to identify and appoint a replacement to comply with the SEBI Listing Regulations regarding Board composition.

The company did not disclose any immediate plans for a successor appointment in this specific communication. Typically, such appointments require shareholder approval at a General Meeting or through a postal ballot, depending on the urgency and existing Board vacancies. Investors should monitor future filings for announcements regarding the nomination of a new Independent Director to restore the Board’s independent strength.